ITM Receives Pharma Trend Award 2018 “Most Innovative Product”
GARCHING, Germany--(BUSINESS WIRE)--Sep 26, 2018--ITM Isotopen Technologien München AG (ITM), a specialized group of radiopharmaceutical companies, announced today that it has received the Pharma Trend Award 2018 “Most Innovative Product” in the start-up category. An interdisciplinary jury of six pharma representatives evaluated the submissions from start-up companies in biotechnology, medical engineering and digital health industries. The 19th edition of the awards ceremony took place on September 18, 2018, in the Deutsches Museum (German Museum) in Munich. The “Best Pharmaceutical Companies in Germany” ranking was also announced at the event in conjunction with the Pharma Trend “Image and Innovation Award”.
The ranking is based on the survey data collected by Pharma Trend, which has been conducting annual surveys among doctors in Germany in the Rx category (prescription drugs) since 2000. As of 2018, it now also surveys 900 doctors and pharmacists in the OTC (pharmacists) and orphan drugs (clinicians) categories. In addition, 600 patients were surveyed in the OTC category. The expansion of the Pharma Trend survey enables pharmaceutical companies to be evaluated by their most important stakeholders (doctors, pharmacists and patients) in Germany in terms of innovation and sustainability. The respondents assess the pharmaceutical companies with regard to the quality of their marketing and sales, the quality of their products and services, innovation, affordability, transparency, responsibility, ethical practices, management quality and business success.
The criteria of patient benefit, innovation, efficient patient care and integration in the German statutory insurance scheme were particularly decisive for the jury in the assessment of the products and projects submitted for the start-ups category, in which ITM took part.
Steffen Schuster, Chief Executive Officer of ITM, said, “We are delighted to receive the ‘Most Innovative Product’ award at Pharma Trend 2018. Winning first place highlights our successful work in the development and preparation of a new generation of targeted cancer diagnostics and treatments. Targeted Radionuclide Therapy is increasingly seen as a promising treatment option for cancer and has already been used successfully for many years under compassionate use. We are confident that our lead candidate Solucin® for the treatment of neuroendocrine tumors, which is currently in phase III clinical trial, will be able to confirm these excellent results and will obtain approval as one of the world’s first therapeutic radiopharmaceuticals. With our Targeted Radionuclide Therapy, we want to make a significant contribution to improve outcomes and quality of life for cancer patients.”
– End –
View source version on businesswire.com:https://www.businesswire.com/news/home/20180926005585/en/
Head of Marketing
Phone: +49 89 3298986-16
Press contact: WE Communications
Senior Account Executive
Phone: +49 89 628175-46
KEYWORD: EUROPE GERMANY
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL
Copyright Business Wire 2018.
PUB: 09/26/2018 09:53 AM/DISC: 09/26/2018 09:53 AM